DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Wegovy's"


5 mentions found


☆ Credit Suisse upgrades Novo Nordisk on 'surprise' growth of obesity and diabetes drugs Ozempic and Wegovy
  + stars: | 2023-04-13 | by ( Michelle Fox | ) www.cnbc.com   time to read: +2 min
Credit Suisse upgraded Danish pharmaceutical company Novo Nordisk to outperform from neutral on Thursday, citing growth in its obesity and diabetes drugs. "Rx trends for both Ozempic and Wegovy YTD have been a major surprise and have significantly outperformed our expectations," he wrote. Now that Wegovy is back in supply, Credit Suisse had expected a potential slowdown in growth for Ozempic. Instead, while there has been a rise in new patients taking Wegovy, Ozempic is continuing to see growth, Dunn said. "Novo sees growth being driven by penetration in diabetes rather than off-label obesity use, which is backed up by the fact the Ozempic growth has accelerated despite re-supply of Wegovy for Obesity," he said.
☆ People Can't Get Ozempic, New Weight-Loss Drugs Because of Broken Healthcare System
  + stars: | 2023-04-13 | by ( ) www.businessinsider.com   time to read: +15 min
Wegovy is just one of a wave of revolutionary weight-loss drugs, which also includes the buzzy Ozempic, that represents a watershed moment for obesity treatment. Demand for weight-loss drugs is surgingDoctors and healthcare professionals searched for a healthy, safe, and effective weight-loss solution for years before the drugs, known collectively as GLP-1 agonists, exploded on the scene. If there is one key that could unlock access to expensive weight-loss drugs for Americans, it's Medicare. Expanding coverage for Ozempic and other weight-loss drugs for just a small segment of the population could cost Medicare up to $26.8 billion a year. Patients lose outYears from now, patients may have an easier time getting their hands on weight-loss drugs.
☆ Top 10 things the Club is watching in the stock market Friday
  + stars: | 2023-03-03 | by ( Jeff Marks | ) www.cnbc.com   time to read: +4 min
Club holding Costco (COST) was a little disappointing Thursday evening, with an earnings beat overshadowed by some softer February trends. Analysts outline five "underappreciated catalysts" that they think will drive a re-rating of the Club holding in the next twelve months. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .
☆ New weight loss drugs trending with billionaires and celebrities are about to enter more American homes
  + stars: | 2023-01-20 | by ( Barbara Collins | ) www.cnbc.com   time to read: +8 min
GLP-1s also have been found to help with weight loss as they make individuals who use them feel fuller for a longer period of time. Using GLP-1s drug injections for weight loss has become one of the latest ways some big names in the market are shedding extra pounds. That's why his company has launched a program to offer GLP-1 drugs and corresponding medical care to individuals struggling with obesity or weight loss issues. Pairing personalized coaching with GLP-1s is the key to effective weight loss treatment, Reitano said, and helping patients maximize their results. A new real-time approach to weight managementReitano said it should not be an either/or scenario involving diabetes management of weight loss and that will change over the next decade.
☆ Looming obesity drug rivalry not a concern for Novo CEO
  + stars: | 2022-11-15 | by ( Natalie Grover Maggie Fick | Natalie Grover | Maggie Fick | ) www.reuters.com   time to read: +4 min
The main active ingredient in Ozempic is semaglutide, which is also the key ingredient in Novo's obesity drug Wegovy. Several less efficacious obesity drugs from multiple drugmakers have previously been approved, but bungled launches and serious side effects led to tepid sales and even some market withdrawals. Novo faces looming competition from Eli Lilly (LLY.N), whose weekly injection Mounjaro won U.S. approval for type 2 diabetes in May and is under fast-track review as a weight-loss drug. Amgen (AMGN.O) also has an early-stage, once-monthly obesity drug that is being keenly watched. Elon Musk, the world's richest person and now Twitter owner, has offered his own endorsement of the weight-loss benefits of semaglutide on the social media website.
<< prev 2 next >>
Total: 5